30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: NuVasive

$177.5MM, +11% (Ex-U.S. +34%)

  • U.S. Lumbar +8%
  • U.S. Biologics +9%
  • U.S. Cervical +9%
  • U.S. Monitoring +11%


  • International driven by strong growth in Europe, Asia Pacific, offset by economy in Latin America
  • Commenced alpha launch of computerized spinal alignment system, beta to come in 2H14
  • Ten product launches for 2014 include Archon Plate for anterior cervical spine
  • Hope to have word from FDA on AttraX by year-end
  • Keeping an eye on sacroiliac fusion, especially how reimbursement plays out
  • Company claims 8% of global spine market